RU2015139359A - Способ ослабления провоспалительной реакции - Google Patents
Способ ослабления провоспалительной реакции Download PDFInfo
- Publication number
- RU2015139359A RU2015139359A RU2015139359A RU2015139359A RU2015139359A RU 2015139359 A RU2015139359 A RU 2015139359A RU 2015139359 A RU2015139359 A RU 2015139359A RU 2015139359 A RU2015139359 A RU 2015139359A RU 2015139359 A RU2015139359 A RU 2015139359A
- Authority
- RU
- Russia
- Prior art keywords
- hydrolyzate
- group
- seq
- subject
- peptides
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims 2
- 230000004054 inflammatory process Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 235000016709 nutrition Nutrition 0.000 claims 3
- 230000000770 proinflammatory effect Effects 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 235000013406 prebiotics Nutrition 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 102000003815 Interleukin-11 Human genes 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 108090000630 Oncostatin M Proteins 0.000 claims 1
- 102100031942 Oncostatin-M Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 1
- 230000001195 anabolic effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229940040504 lipotropic agent Drugs 0.000 claims 1
- 239000003912 lipotropic agent Substances 0.000 claims 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (13)
1. Способ подавления провоспалительной реакции, лечения воспалительного заболевания и/или снижения уровня в провоспалительного цитокина у субъекта, включающий введение композиции, содержащей гидролизат казеина, в субъект, в котором гидролизат состоит из пептидов с молекулярной массой более чем 500 Да.
2. Способ по п. 1, в котором воспалительное заболевание выбирается из группы, состоящей из диабета типа 1, болезни Крона, язвенного колита, метаболического синдрома, HLA-DQ8-ассоциированных заболеваний, HLA-DQ2-ассоциированных заболеваний и целиакии.
3. Способ по п. 2, в котором провоспалительный цитокин выбирается из группы, состоящей из IL-1, IL-6, IL-8, TNF-α, TNF-β, членов семейства IL-20, IL-33, LIF, IFN-γ, OSM, CNTF, TGF-β, GM-CSF, IL-11, IL-12, IL-17, IL-18 и их комбинации.
4. Способ по п. 1, в котором гидролизат содержит по меньшей мере три пептида, выбранных из группы, состоящей из SEQ ID NO: 1-68.
5. Способ по п. 4, в котором гидролизат содержит по меньшей мере три пептида, выбранных из группы, состоящей из SEQ ID NO: 1-24.
6. Способ по п. 5, в котором гидролизат содержит по меньшей мере три пептида, выбранных из группы, состоящей из SEQ ID NO: 1-15.
7. Способ по п. 4, в котором гидролизат содержит пептид с SEQ ID NO: 1 и по меньшей мере три пептида, выбранных из группы, состоящей из SEQ ID NO: 2-68.
8. Способ по п. 1, в котором гидролизат вводится в пищевой композиции, содержащей липид или жировую фазу и источник белка.
9. Способ по п. 8, в котором пищевая композиция содержит от примерно 0,1 до примерно 1 г/100 ккал пребиотической композиции, где пребиотическая композиция содержит по меньшей мере 20% олигосахарида.
10. Способ по п. 8, в котором питательная композиция дополнительно содержит от примерно 5 до примерно 100 мг/100 ккал источника длинноцепочечных полиненасыщенных жирных кислот, который содержит докозагексановую кислоту.
11. Способ по п. 10, в котором питательная композиция дополнительно содержит арахидоновую кислоту.
12. Способ по п. 1, в котором субъектом является человеческое дитя или подросток.
13. Способ по п. 1, в котором питательная композиция дополнительно содержит один или несколько углеводов, нуклеиновых кислот, липидов, минералов, анаболических питательных веществ, витаминов, антиоксидантов, пробиотических штаммов бактерий и липотропных агентов.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/838,539 US9352020B2 (en) | 2013-03-15 | 2013-03-15 | Reducing proinflammatory response |
| US13/838,539 | 2013-03-15 | ||
| PCT/US2014/023637 WO2014150571A1 (en) | 2013-03-15 | 2014-03-11 | Reducing proinflammatory response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015139359A true RU2015139359A (ru) | 2017-04-24 |
Family
ID=50391507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015139359A RU2015139359A (ru) | 2013-03-15 | 2014-03-11 | Способ ослабления провоспалительной реакции |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9352020B2 (ru) |
| EP (1) | EP2968437B1 (ru) |
| CN (1) | CN105142658B (ru) |
| AR (1) | AR095336A1 (ru) |
| AU (1) | AU2014237027C1 (ru) |
| BR (1) | BR112015018259A2 (ru) |
| CA (1) | CA2905820A1 (ru) |
| ES (1) | ES2821750T3 (ru) |
| MX (1) | MX2015011938A (ru) |
| MY (1) | MY177369A (ru) |
| PE (1) | PE20151947A1 (ru) |
| PH (1) | PH12015502102B1 (ru) |
| RU (1) | RU2015139359A (ru) |
| SG (1) | SG11201505693WA (ru) |
| TW (1) | TW201505647A (ru) |
| WO (1) | WO2014150571A1 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016172479A1 (en) * | 2015-04-22 | 2016-10-27 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes |
| US20170020950A1 (en) * | 2015-07-23 | 2017-01-26 | Mead Johnson Nutrition Company | Methods for modulating kinases |
| MX2018005663A (es) * | 2015-11-09 | 2018-08-01 | Mjn Us Holdings Llc | Composiciones nutricionales que comprenden un hidrolizado de caseina, asi como butirato alimenticio y/o un compuesto para estimular la formacion de butirato endogeno. |
| US10034937B2 (en) | 2015-12-04 | 2018-07-31 | Mead Johnson Nutrition Company | Synergistic nutritional compositions and uses thereof |
| RU2659240C2 (ru) * | 2016-05-23 | 2018-06-29 | федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) | Способ получения функционального продукта питания для реабилитации онкологических больных |
| US20180160714A1 (en) * | 2016-12-12 | 2018-06-14 | Mead Johnson Nutrition Company | Nutritional compositions containing butyrate and uses thereof |
| KR102665545B1 (ko) | 2017-04-17 | 2024-05-13 | 더 유니버서티 오브 시카고 | 인간 건강에의 적용 및 질환의 치료를 위한 장으로의 단쇄 지방산의 전달을 위한 중합체 재료 |
| US20190208807A1 (en) | 2018-01-05 | 2019-07-11 | Mead Johnson Nutrition Company | Nutritional compositions containing milk-derived peptides and uses thereof |
| CN108967557A (zh) * | 2018-09-29 | 2018-12-11 | 贝因美（杭州）食品研究院有限公司 | 一种婴儿配方食品及其制备方法 |
| CN110204595A (zh) * | 2019-06-04 | 2019-09-06 | 海普诺凯营养品有限公司 | 一种具有调节b淋巴细胞活性的羊乳酪蛋白水解肽及其制备方法 |
| GB2608587B (en) * | 2021-06-25 | 2025-01-01 | Mjn Us Holdings Llc | Use of extensively hydrolysed protein |
| CN114989247B (zh) * | 2022-04-27 | 2024-04-02 | 中南林业科技大学 | 一种牦牛奶渣抗缺氧或低氧、抗疲劳肽及其制备方法和应用 |
| CN117384270B (zh) * | 2023-10-13 | 2024-07-16 | 华南理工大学 | 一种酪蛋白源dpp-iv抑制六肽及其制备方法与应用 |
| WO2026003044A1 (en) * | 2024-06-25 | 2026-01-02 | Ntd Labs, S.L. | Casein hydrolysate for treating crohn's disease |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2064092C2 (de) | 1970-12-28 | 1983-06-01 | Bayer Ag, 5090 Leverkusen | Inhibitoren für Glykosidhydrolasen aus Actinomyceten |
| US3937817A (en) | 1973-02-28 | 1976-02-10 | Bayer Aktiengesellschaft | Pharmaceutical compositions containing a saccharase inhibitor |
| GB1475624A (en) | 1974-07-22 | 1977-06-01 | Toyama Chemical Co Ltd | Polypeptide |
| FR2474828B1 (fr) | 1980-02-01 | 1983-09-09 | Agronomique Inst Nat Rech | Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application |
| FR2474829B1 (fr) | 1980-02-01 | 1983-09-09 | Agronomique Inst Nat Rech | Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications |
| US4491589A (en) | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
| DK589785A (da) | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
| IT1190349B (it) | 1986-06-16 | 1988-02-16 | Prodotti Formenti Srl | Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle |
| FR2608050B1 (fr) | 1986-12-15 | 1990-04-13 | Bellon Labor Sa Roger | Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique |
| US5230902A (en) | 1988-04-29 | 1993-07-27 | Immunotec Research Corporation | Undenatured whey protein concentrate to improve active systemic humoral immune response |
| US5102871A (en) | 1989-04-24 | 1992-04-07 | Kyowa Hakko Kogyo Co., Ltd. | Nutrient composition |
| FI904074A7 (fi) | 1989-08-28 | 1991-03-01 | Milupa Ag | Optimoidun aminohappokoostumuksen omaavat proteiini-, peptidi- ja aminohapposeokset sekä niiden käyttö keskosten ja rintalasten ravinnon sekä äidinmaidon lisäaineiden valmistamiseksi |
| US5407957A (en) | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
| PH30997A (en) | 1990-03-12 | 1997-12-23 | Ciba Geigy | Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes. |
| JP2731035B2 (ja) | 1991-01-24 | 1998-03-25 | マーテック・コーポレイション | 微生物油混合物およびその使用 |
| US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
| GB9310472D0 (en) | 1993-05-20 | 1993-07-07 | Univ Warwick | Phenylalanine-free protein and dna coding thereof |
| GB9312369D0 (en) | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
| US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
| US5723446A (en) | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
| US5714472A (en) | 1993-12-23 | 1998-02-03 | Nestec Ltd. | Enternal formulation designed for optimized nutrient absorption and wound healing |
| US5605893A (en) | 1994-03-15 | 1997-02-25 | Children's Hospital Of Los Angeles | Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients |
| WO1996014577A1 (en) | 1994-11-04 | 1996-05-17 | The National Child Health Research Foundation | Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected |
| US5643880A (en) | 1994-05-26 | 1997-07-01 | Abbott Laboratories | Product for inhibition of attachment of H. influenzae to human cells |
| US5821217A (en) | 1995-10-27 | 1998-10-13 | Beth Israel Deaconess Medical Center, Inc. | Enteral formulation: low in fat and containing protein hydrolysates |
| IT1277964B1 (it) | 1995-12-27 | 1997-11-12 | Biosistema Di Pier Luigi Spara | Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso |
| KR100194074B1 (ko) | 1996-02-21 | 1999-06-15 | 박종헌 | 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제 |
| CA2260892A1 (en) | 1996-07-17 | 1998-01-22 | Nicada, Inc. | Appetite suppression |
| KR100221124B1 (ko) | 1996-09-23 | 1999-10-01 | 한상기 | 신규한 카제인 및 그 제조방법 |
| NL1005037C2 (nl) | 1997-01-17 | 1998-07-20 | Nl Zuivelonderzoek Inst | Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten. |
| CA2340223A1 (en) | 1998-08-12 | 2000-02-24 | Morinaga Milk Industry Co., Ltd. | Nutritional compositions for preventing or treating hyperlipoproteinemia |
| US6077558A (en) | 1998-12-23 | 2000-06-20 | Bristol-Myers Squibb Company | Elemental nutritional products |
| US6905702B1 (en) | 1999-11-08 | 2005-06-14 | Children's Hospital Los Angeles | Methods for regulating blood glucose and appetite suppression in type 2 diabetics |
| GB9927603D0 (en) | 1999-11-22 | 2000-01-19 | Nestle Sa | Use of a milk protein hydrolysate in the treatment of diabetes |
| ATE320724T1 (de) | 1999-12-30 | 2006-04-15 | Kerry Group Services Ltd | Aufbaupräparat, das kohlenhydrat- und peptidmaterial enthält und sein gebrauch als energieergänzung nach oder während körperlicher übung oder als metabolischer nährstoff für die orale verabreichung |
| NL1014380C2 (nl) | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
| US6207638B1 (en) | 2000-02-23 | 2001-03-27 | Pacifichealth Laboratories, Inc. | Nutritional intervention composition for enhancing and extending satiety |
| IL134830A0 (en) | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
| US7666996B2 (en) | 2000-03-01 | 2010-02-23 | Peptera Pharmaceuticals Ltd | Casein derived peptides and uses thereof |
| TWI268138B (en) | 2000-05-11 | 2006-12-11 | Kanebo Seiyaku Ltd | Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same |
| DE60127675T2 (de) | 2000-06-28 | 2007-12-27 | Fuji Nihon Seito Corp. | Neuartige insulin synthase und verfahren zur herstellung von insulin durch anwendung derselben |
| GB0016189D0 (en) | 2000-06-30 | 2000-08-23 | Pepsyn Ltd | Cosmetic composition |
| AU9037401A (en) | 2000-09-08 | 2002-03-22 | New Zealand Dairy Board | Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders |
| AU1142001A (en) | 2000-10-19 | 2002-04-29 | Dsm N.V. | Protein hydrolysates |
| WO2003005836A2 (en) | 2001-07-10 | 2003-01-23 | Trustees Of Boston University | Modified-fat nutritional products useful for preventing or treating obesity |
| ATE372689T1 (de) | 2001-07-18 | 2007-09-15 | Dsm Ip Assets Bv | Verfahren zur hydrolyse von milcheiweissen |
| DE10149668A1 (de) | 2001-10-09 | 2003-04-10 | Numico Res B V | Insulinmimetische Aminosäuresequenzen |
| JP2003137804A (ja) | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−１８誘導剤 |
| ATE353336T1 (de) | 2001-11-21 | 2007-02-15 | Morinaga Milk Industry Co Ltd | Neues peptid mit angiotensinkonvertase hemmender wirkung |
| EP1359157A1 (en) | 2002-04-29 | 2003-11-05 | Société des Produits Nestlé S.A. | Metallo-proteinase inhibitory agent |
| US7460960B2 (en) | 2002-05-10 | 2008-12-02 | Epitome Biosystems, Inc. | Proteome epitope tags and methods of use thereof in protein modification analysis |
| ES2540926T3 (es) | 2002-06-04 | 2015-07-14 | Dsm Ip Assets B.V. | Hidrolizado de proteínas rico en tripéptidos |
| FR2841473B1 (fr) | 2002-06-27 | 2004-09-17 | Ingredia | Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires |
| US7648957B2 (en) | 2002-09-04 | 2010-01-19 | Dsm Ip Assets B.V. | Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction |
| TWI317636B (en) | 2002-11-22 | 2009-12-01 | Meiji Dairies Corp | Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress |
| JPWO2004050118A1 (ja) | 2002-11-29 | 2006-03-30 | 森永乳業株式会社 | プロテアーゼ阻害剤 |
| JP3955885B2 (ja) | 2002-12-29 | 2007-08-08 | 日産化学工業株式会社 | アディポネクチン受容体及びそれをコードする遺伝子 |
| EP1619957A1 (en) | 2003-05-05 | 2006-02-01 | Unilever N.V. | Hydrolysed casein product comprising tripeptides ipp and/ or vpp |
| US8524225B2 (en) | 2003-09-23 | 2013-09-03 | Dsm Ip Assets B.V. | Use of proline specific endoproteases to hydrolyse peptides and proteins |
| EP1935425A3 (en) | 2003-10-24 | 2008-09-03 | N.V. Nutricia | Immunemodulating oligosaccharides for the treatment and/or prevention of chronic obstructive pulmonary disease (COPD) |
| BE1015863A6 (nl) | 2004-01-19 | 2005-10-04 | Huybrechts Lucas | Anticariogene proteinen & peptiden & sacchariden. |
| EP1718158B1 (en) | 2004-01-28 | 2014-07-02 | Andromeda Bio Tech Ltd. | Hsp therapy in conjunction with a low antigenicity diet |
| EP1568707A1 (en) | 2004-02-26 | 2005-08-31 | Puleva Biotech, S.A. | Antihypertensive peptides from casein hydrolysates |
| MXPA06010014A (es) | 2004-03-01 | 2007-03-07 | Peptera Pharmaceuticals Ltd | Peptidos derivados de la caseina y usos terapeuticos de los mismos. |
| US20080221023A1 (en) | 2004-05-27 | 2008-09-11 | Campina Nederland Holding | Use of Protein Hydrolysates For the Manufacture of a Medicament For Prophylaxis and/or Treatment of a Dpp-IV Mediated Condition |
| US8252769B2 (en) * | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| DE102004040452A1 (de) | 2004-08-20 | 2006-02-23 | N.V. Nutricia | Peptidgemisch |
| KR100560127B1 (ko) | 2004-09-04 | 2006-03-13 | 한국기초과학지원연구원 | 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법 |
| AU2005302852B2 (en) | 2004-11-12 | 2011-06-02 | N.V. Nutricia | Food composition comprising a protein-and a lipid fraction for rapidly attenuating inflammatory responses |
| ES2381118T3 (es) | 2004-12-23 | 2012-05-23 | Campina Nederland Holding B.V. | Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso |
| JP2008527020A (ja) | 2005-01-18 | 2008-07-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | 新規な栄養補助組成物 |
| PL1843778T3 (pl) | 2005-02-03 | 2010-06-30 | Dsm Ip Assets Bv | Kompozycje zawierające galusan epigalokatechiny i hydrolizat białkowy |
| ES2321650T3 (es) | 2005-02-09 | 2009-06-09 | Unilever N.V. | Productos alimenticios que comprenden solidos lacteos hidrolizados con sabor mejorado. |
| WO2006114439A2 (en) | 2005-04-28 | 2006-11-02 | Dsm Ip Assets B.V. | Novel nutraceutical compositions |
| ATE497704T1 (de) | 2005-04-28 | 2011-02-15 | Unilever Nv | Gesundheitsfördernde peptide und sie enthaltende zusammensetzungen |
| US20090074893A1 (en) | 2005-04-29 | 2009-03-19 | Campina Nederland Holding B.V. | Antiviral peptides |
| ES2319475B1 (es) | 2005-06-08 | 2010-02-16 | Consejo Superior Investig. Cientificas | Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion. |
| PT1898724E (pt) | 2005-07-01 | 2010-11-26 | Nutricia Nv | Nutrição infantil com proteínas hidrolisadas |
| GB0523806D0 (en) | 2005-11-23 | 2006-01-04 | Micromass Ltd | Mass spectrometer |
| US8431531B2 (en) | 2005-11-30 | 2013-04-30 | Campina Nederland Holding B.V. | Methods for stimulating glucagon-like peptide-1(GLP-1) secretion and treatments comprising same |
| WO2008054192A1 (en) | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
| PT1800675E (pt) | 2005-12-23 | 2011-08-30 | Nutricia Nv | COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA |
| JP5096173B2 (ja) | 2006-02-09 | 2012-12-12 | カルピス株式会社 | 経口摂取用関節リウマチ抑制剤 |
| WO2007107587A2 (en) | 2006-03-22 | 2007-09-27 | Dsm Ip Assets B.V. | Cholesterol lowering protein hydrolysates |
| EA200802128A1 (ru) | 2006-04-12 | 2009-04-28 | ДСМ АйПи АССЕТС Б.В. | Новые нутрицевтические композиции |
| CA2649842C (en) | 2006-04-21 | 2015-02-17 | Meiji Seika Kaisha, Ltd. | Composition containing peptide as active ingredient |
| WO2007125946A1 (ja) | 2006-04-28 | 2007-11-08 | Snow Brand Milk Products Co., Ltd. | ペプチド |
| KR20080003637A (ko) | 2006-07-03 | 2008-01-08 | 한상기 | 다이어트효과가 우수한 기능성 유산균발효조성물 |
| WO2008015374A2 (en) | 2006-08-04 | 2008-02-07 | Shs International Ltd | Protein free formula |
| EP2049091B1 (en) | 2006-08-09 | 2010-12-29 | DSM IP Assets B.V. | Casein complexes |
| NL1032840C2 (nl) | 2006-11-09 | 2008-05-13 | Friesland Brands Bv | Probiotische hydrolysaatvoeding voor kinderen. |
| NL1033521C2 (nl) | 2007-03-08 | 2008-09-09 | Friesland Brands Bv | Kindervoedingen met geoptimaliseerde aminozuursamenstelling. |
| WO2008127031A1 (en) | 2007-04-12 | 2008-10-23 | Industry-Academic Cooperation Foundation, Yonsei University | Magnetic resonance imaging contrast agents comprising zinc-containing magnetic metal oxide nanoparticles |
| CA2687117A1 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| CA2688293A1 (en) | 2007-05-25 | 2008-12-04 | Childrens's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
| WO2008153429A2 (en) | 2007-06-11 | 2008-12-18 | Uniwersytet Jagiellonski | A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use |
| EP2187916A2 (en) | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of gluten exorphin c as a therapeutic agent |
| EP2230300A4 (en) | 2007-10-24 | 2012-08-08 | Otsuka Chemical Holdings Co Ltd | POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION |
| PT2285387E (pt) * | 2008-06-13 | 2016-02-09 | Nutricia Nv | Nutrição para a prevenção de infeções |
| US8859210B2 (en) | 2008-10-17 | 2014-10-14 | Mead Johnson Nutrition Company | Method for identifying allergenic proteins and peptides |
| JP5735734B2 (ja) | 2009-04-16 | 2015-06-17 | 雪印メグミルク株式会社 | 脂質代謝改善剤 |
| EP2253324A1 (en) | 2009-04-30 | 2010-11-24 | Consejo Superior De Investigaciones Cientificas | Use of a casein-derived peptide and compositions thereof as antihypertensive |
| EP2295535A1 (en) | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotic material |
| EP2332428B1 (en) | 2009-12-04 | 2014-08-20 | MJN U.S. Holdings LLC | Nutritional Formulation comprising a cow's milk peptide-containing hydrolysate and/or peptides derived thereof for tolerance induction |
| CA2786710C (en) | 2010-01-19 | 2018-10-09 | Abbott Laboratories | Nutritional formulas containing synbiotics |
| AU2011221270A1 (en) | 2010-02-24 | 2012-09-13 | Morinaga Milk Industry Co.,Ltd. | Therapeutic agent for eating disorders |
| PH12013501382A1 (en) * | 2010-12-31 | 2013-09-02 | Abbott Lab0Ratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers or children using human milk oligosaccharides |
| EP2514435A1 (en) | 2011-04-19 | 2012-10-24 | Nestec S.A. | Infant formula for use in the prevention of cardiovascular diseases |
-
2013
- 2013-03-15 US US13/838,539 patent/US9352020B2/en active Active
-
2014
- 2014-03-11 CN CN201480015639.5A patent/CN105142658B/zh active Active
- 2014-03-11 SG SG11201505693WA patent/SG11201505693WA/en unknown
- 2014-03-11 ES ES14714100T patent/ES2821750T3/es active Active
- 2014-03-11 CA CA2905820A patent/CA2905820A1/en not_active Abandoned
- 2014-03-11 MX MX2015011938A patent/MX2015011938A/es unknown
- 2014-03-11 PE PE2015001982A patent/PE20151947A1/es not_active Application Discontinuation
- 2014-03-11 AU AU2014237027A patent/AU2014237027C1/en not_active Ceased
- 2014-03-11 RU RU2015139359A patent/RU2015139359A/ru unknown
- 2014-03-11 EP EP14714100.6A patent/EP2968437B1/en active Active
- 2014-03-11 MY MYPI2015702447A patent/MY177369A/en unknown
- 2014-03-11 BR BR112015018259A patent/BR112015018259A2/pt not_active IP Right Cessation
- 2014-03-11 WO PCT/US2014/023637 patent/WO2014150571A1/en not_active Ceased
- 2014-03-14 AR ARP140101039A patent/AR095336A1/es unknown
- 2014-03-14 TW TW103109610A patent/TW201505647A/zh unknown
-
2015
- 2015-09-14 PH PH12015502102A patent/PH12015502102B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ710033A (en) | 2020-09-25 |
| PE20151947A1 (es) | 2016-01-20 |
| AU2014237027C1 (en) | 2019-06-06 |
| PH12015502102A1 (en) | 2016-01-11 |
| US9352020B2 (en) | 2016-05-31 |
| HK1216995A1 (zh) | 2016-12-16 |
| MY177369A (en) | 2020-09-14 |
| ES2821750T3 (es) | 2021-04-27 |
| SG11201505693WA (en) | 2015-08-28 |
| MX2015011938A (es) | 2015-12-01 |
| EP2968437B1 (en) | 2020-07-29 |
| AU2014237027A1 (en) | 2015-08-13 |
| TW201505647A (zh) | 2015-02-16 |
| BR112015018259A2 (pt) | 2017-08-22 |
| EP2968437A1 (en) | 2016-01-20 |
| PH12015502102B1 (en) | 2021-06-23 |
| US20140271554A1 (en) | 2014-09-18 |
| CA2905820A1 (en) | 2014-09-25 |
| CN105142658B (zh) | 2018-10-23 |
| AU2014237027B2 (en) | 2019-02-28 |
| WO2014150571A1 (en) | 2014-09-25 |
| CN105142658A (zh) | 2015-12-09 |
| AR095336A1 (es) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015139359A (ru) | Способ ослабления провоспалительной реакции | |
| Siddiqui et al. | The immunomodulatory functions of butyrate | |
| Andrade et al. | The role of immunomodulators on intestinal barrier homeostasis in experimental models | |
| Bauer et al. | Influence of the gastrointestinal microbiota on development of the immune system in young animals | |
| Zentek et al. | Nutritional and physiological role of medium-chain triglycerides and medium-chain fatty acids in piglets | |
| Marion-Letellier et al. | IBD: in food we trust | |
| RU2011105430A (ru) | Питательная композиция для содействия здоровому развитию и росту | |
| Nguyen et al. | Growth performance and immune status in common carp Cyprinus carpio as affected by plant oil-based diets complemented with β-glucan | |
| ES2736313T3 (es) | Composiciones nutricionales que contienen un componente peptídico con propiedades antiinflamatorias y usos de las mismas | |
| RU2013146517A (ru) | Композиции и способы, пригодные для облегчения возрастных заболеваний | |
| MY189402A (en) | Optimized nutrient fatty acid composition | |
| Mudroňová et al. | Effect of fungal gamma-linolenic acid and beta-carotene containing prefermented feed on immunity and gut of broiler chicken | |
| RU2015139557A (ru) | Уменьшение риска развития аутоимунного заболевания | |
| WO2006112694A2 (en) | Nutritional supplement with colostrum and epa or dha or gla | |
| RU2008107342A (ru) | Питание для пациентов, страдающих ожирением | |
| Nur Mahendra et al. | Omega‐6: Its Pharmacology, Effect on the Broiler Production, and Health | |
| Mun et al. | Anti-obesity and immunomodulatory effects of oil and fermented extract dried from Tenebrio molitor larvae on aged obese mice | |
| Satyaraj | Emerging paradigms in immunonutrition | |
| RU2015133023A (ru) | Активация адипонектина с использованием гидролизата казеина | |
| Santiago-Lopez et al. | Potential use of food protein-derived peptides in the treatment of inflammatory diseases | |
| Chand | Nutrition as a key weapon in strengthening immune system relative to pandemic novel Coronavirus disease (COVID-19): A review | |
| Maroufyan et al. | Effect of dietary combination of methionine and fish oil on cellular immunity and plasma fatty acids in infectious bursal disease challenged chickens | |
| RU2015139971A (ru) | Питательные композиции, содержащие пептидный компонент, и их применение | |
| Park et al. | Monocyte chemoattractant protein-1 polymorphism interaction with spirulina immunomodulatory effects in healthy Korean elderly: A 16 week, double-blind randomized clinical trial | |
| Chavali et al. | The Role of ω-3 Polyunsaturated Fatty Acids on Immune Responses During Infection and Inflammation |